Article
Response of the ENPP1-Deficient Skeletal Phenotype to Oral Phosphate Supplementation and/or Enzyme Replacement Therapy: Comparative Studies in Humans and Mice.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research - 1 May 2021
Ferreira Carlos R, Kavanagh Dillon, Oheim Ralf, Zimmerman Kristin, Stürznickel Julian, Li Xiaofeng, Stabach Paul, Rettig R Luke, Calderone Logan, MacKichan Colin, Wang Aaron, Hutchinson Hunter A, Nelson Tracy, Tommasini Steven M, von Kroge Simon, Fiedler Imke Ak, Lester Ethan R, Moeckel Gilbert W, Busse Björn, Schinke Thorsten, Carpenter Thomas O, Levine Michael A, Horowitz Mark C, Braddock Demetrios T
Abstract excerpt
Inactivating mutations in human ecto-nucleotide pyrophosphatase/phosphodiesterase-1 (ENPP1) may result in early-onset osteoporosis (EOOP) in haploinsufficiency and autosomal recessive hypophosphatemic rickets (ARHR2) in homozygous deficiency. ARHR2 patients are frequently treated with phosphate supplementation to ameliorate the rachitic phenotype, but elevating plasma phosphorus concentrations in ARHR2 patients...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
